Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

2

Other

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Adrenergic receptor beta

2

Serotonin 1a (5-HT1a) receptor

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1982

2

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Hypertension

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Sandoz

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

ECHA (EC/EINECS)

3

FDA UNII

3

PUBCHEM

3

CHEBI

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

CARDIOVASCULAR SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

BETA BLOCKING AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

BETA BLOCKING AGENTS

1

BETA BLOCKING AGENTS AND OTHER DIURETICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Beta blocking agents, non-selective

1

Beta blocking agents, non-selective, and other diuretics

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

Pindolol

BJ4HF6IU1D

Export Data
Search for Structure

Status:

US Approved Rx (1994)

First approved in 1982

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Adrenergic receptor beta

Serotonin 1a (5-HT1a) receptor

Conditions:

Pindolol was developed at Sandoz at 1960s. Pindolol is a nonselective beta-adrenergic antagonist (beta-blocker) which possesses intrinsic sympathomimetic activity (partial agonist activity) in therapeutic dosage ranges but does not possess quinidine-...

like membrane stabilizing activity. The partial beta-adrenergic agonistic activity of pindolol in the heart appears to be completely restricted to the sinoatrial pacemaker. In standard pharmacologic tests in man and animals, Pindolol attenuates increases in heart rate, systolic blood pressure, and cardiac output resulting from exercise and isoproterenol administration, thus confirming its beta-blocking properties. In addition to beta-adrenergic activity pindolol demonstrates mixed agonist-antagonist activity at central 5-HT receptors. Although in accordance with the hypothesis that pindolol increases the antidepressant effects of selective serotonin reuptake inhibitors by antagonism of 5-HT at inhibitory 5-HT1A autoreceptors, pindolol possesses partial agonist activity at 5-HT1A receptors. Pindolol tablets are indicated in the management of hypertension.

DIHYDRORESORCINOL

6UK3D2BXJT

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

Pindolol hydrochloride

2XEX32G2GD

Export Data
Search for Structure

Status:

US Approved Rx (1994)

First approved in 1982

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Adrenergic receptor beta

Serotonin 1a (5-HT1a) receptor

Conditions:

Pindolol was developed at Sandoz at 1960s. Pindolol is a nonselective beta-adrenergic antagonist (beta-blocker) which possesses intrinsic sympathomimetic activity (partial agonist activity) in therapeutic dosage ranges but does not possess quinidine-...

like membrane stabilizing activity. The partial beta-adrenergic agonistic activity of pindolol in the heart appears to be completely restricted to the sinoatrial pacemaker. In standard pharmacologic tests in man and animals, Pindolol attenuates increases in heart rate, systolic blood pressure, and cardiac output resulting from exercise and isoproterenol administration, thus confirming its beta-blocking properties. In addition to beta-adrenergic activity pindolol demonstrates mixed agonist-antagonist activity at central 5-HT receptors. Although in accordance with the hypothesis that pindolol increases the antidepressant effects of selective serotonin reuptake inhibitors by antagonism of 5-HT at inhibitory 5-HT1A autoreceptors, pindolol possesses partial agonist activity at 5-HT1A receptors. Pindolol tablets are indicated in the management of hypertension.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1